Stem Cell Transplant for Immunologic or Histiocytic Disorders
Status:
Completed
Trial end date:
2014-08-01
Target enrollment:
Participant gender:
Summary
This study tests the clinical outcomes of a preparative regimen of fludarabine (FLU),
anti-thymocyte globulin (ATG)/or Campath, and melphalan; followed by hematopoietic stem cell
transplant, and a post transplant regimen of Cyclosporin A (CsA) in patients with immunologic
or histiocytic disorders. The researchers hypothesize that this regimen will have a positive
effect on post transplant engraftment and the incidence of graft-versus-host-disease (GVHD).
Patients will be randomized biologically into one of 3 arms based upon donor availability:
(a) human leukocyte antigen (HLA) genotypic matched sibling donor, (b) HLA phenotypic matched
unrelated peripheral blood stem cell (PBSC) donor, (c) two HLA 0-2 antigen mismatched
unrelated cord blood donors (double cord).